These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38059421)

  • 1. Severe multi-refractory Sneddon-Wilkinson disease, with fast response to oral roflumilast treatment.
    Peñuelas Leal R; Grau Echevarría A; Labrandero Hoyos C; Blaya Imbernon D; Lorca Sprohnle J; Finello M; Mayo Martinez F; Zaragoza Ninet V
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e467-e469. PubMed ID: 38059421
    [No Abstract]   [Full Text] [Related]  

  • 2. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 3. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
    Smith B; Collier MR; Wu JJ
    JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
    [No Abstract]   [Full Text] [Related]  

  • 5. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
    Lebwohl MG; Hebert AA; Gooderham MJ
    JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].
    Shmelev EI; Shmeleva NM
    Ter Arkh; 2012; 84(6):73-6. PubMed ID: 22997924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
    Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
    Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
    J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast: A potential drug for the treatment of cognitive impairment?
    Sugin LJS; Murugesan A; Bindu M; Sunil KN
    Neurosci Lett; 2020 Sep; 736():135281. PubMed ID: 32735939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist.
    Salvator H; Naline E; Brollo M; Tenor H; Grassin-Delyle S; Devillier P
    Fundam Clin Pharmacol; 2021 Aug; 35(4):725-731. PubMed ID: 33145785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study.
    Salvesen ØNU; Davidsen JR; Pottegård A; Henriksen DP
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):314-319. PubMed ID: 29569375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
    Facius A; Marostica E; Gardiner P; Watz H; Lahu G
    Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
    Vollert S; Kaessner N; Heuser A; Hanauer G; Dieckmann A; Knaack D; Kley HP; Beume R; Weiss-Haljiti C
    Diabetologia; 2012 Oct; 55(10):2779-2788. PubMed ID: 22790061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
    Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
    Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
    Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
    J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
    Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.